Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has accelerated into the deal and paid $90 million upfront for small ...
Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary ...
Capital Brief on MSN
Atlas Arteria shares jump 12.5% following IFM takeover bid
More news: Atlas Arteria shares surged 12.47% by 10.39am (AEST) after resuming trading following a pause as it updated the ...
Industry super’s IFM Investors has strangled tollroads investor Atlas Arteria with its kitbag of raids, creeps and boardroom games, so it may as well finish the job. The only problem is its intent on ...
Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results